巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Equillium

    EQ
    2.070
    0.050
    2.48%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Equillium - 延遲價格・最後更新於 01/07 7:24
    最高位
    2.105
    最低位
    2.070
    開市價
    --
    前收市價
    2.020
    成交量(千)
    0.01
    成交額(百萬)
    0.00
    買入
    2.070
    賣出
    2.130
    每手股數
    --
    市值(百萬)
    70.95
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    7.120 - 1.660
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Equillium
    證券代碼
    EQ.US
    所屬板塊
    Biotechnology
    公司業務
    Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
    發行量
    34275898
    公司總部
    2223 Avenida De La Playa, Suite 105
    公司網址
    https://www.equilliumbio.com
    公司電郵
    ir@equilliumbio.com
    公司電話
    +1 858 412-5302
    暫無內容

    關於

    Equillium(EQ.US)所屬的行業板塊為Biotechnology。
    Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
    詳細公司背景可參考: https://www.equilliumbio.com